Buprenorphine Nanoparticles Sustained Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current buprenorphine formulations for pain and addiction treatment in animals have limitations, including short half-life, low bioavailability, ease of abuse, and frequent administration requirements, which necessitate the development of more effective and sustained release formulations.
Innovation Solution
Stable nanoparticle compositions comprising buprenorphine and biodegradable polymers, such as PLGA, PLA, and PCL, that provide prolonged release profiles, improved bioavailability, and reduced administration frequency, with customizable drug-to-polymer ratios and release durations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If currently approved dosage forms (sublingual tablets, transdermal patches, parenteral formulations) are used, then immediate therapeutic effect is achieved, but frequent administration is required (4-6 injections per day for parenteral formulations)
Solution Approach 1:
The patent segments the drug delivery system into nanoparticle carriers containing buprenorphine, which are then administered via implantable devices. This segmentation allows the drug to be released gradually over extended periods (weeks to months) rather than requiring frequent bolus administrations, thereby resolving the contradiction between immediate effect and prolonged duration.
Solution Approach 2:
The patent employs preliminary action by pre-loading buprenorphine into nanoparticle formulations and implanting them before the need for frequent dosing arises. The implantable devices are prepared in advance to provide sustained release over weeks or months, eliminating the need for repeated administrations while maintaining therapeutic levels.
2Ease of operation
If sublingual tablets are used for buprenorphine administration, then ease of administration is improved, but ease of operation deteriorates due to high abuse potential and psychological dependence
Solution Approach 1:
The patent introduces an intermediary controlled-release mechanism between the patient and the drug. The implantable nanoparticle devices act as a mediator that delivers buprenorphine at controlled rates, preventing the rapid onset associated with abuse while maintaining therapeutic efficacy. This intermediary system eliminates the self-administration aspect that enables abuse.
Solution Approach 2:
The patent employs disposable implantable devices that are inserted once and provide sustained release for weeks or months without requiring patient interaction. These single-use implants eliminate the recurring administration opportunities that lead to abuse and dependence associated with reusable formulations like sublingual tablets.
3Ease of operation
If transdermal patches are used, then non-invasive administration is achieved, but bioavailability is reduced due to low absorption
Solution Approach 1:
The patent changes the physical parameters of drug delivery by using nanoparticle formulations with specific size distributions (50-500 nm) and surface characteristics that enhance absorption. The nanoparticles are engineered to optimize dissolution and permeation rates, achieving high bioavailability while maintaining non-invasive or minimally invasive administration through implants.
4Duration of action of moving object
If parenteral formulations are used for sustained release, then duration of action is improved, but device complexity increases due to implantation procedures and surgical removal requirements
Solution Approach 1:
The patent employs biodegradable polymer matrices that dissolve and degrade in the body after delivering the drug over the intended period (weeks to months). These disposable implants eliminate the need for surgical removal procedures, reducing device complexity and patient burden while maintaining sustained release capabilities.
Solution Approach 2:
The patent utilizes self-service mechanisms where the implantable devices automatically degrade and dissolve in the body after completing their drug delivery function. The biodegradable materials perform the 'removal' service themselves by breaking down into harmless byproducts that are naturally excreted, eliminating the need for complex surgical retrieval procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stable nanoparticle compositions offer sustained release of buprenorphine over several days to months, reducing abuse potential and frequency of administration, while maintaining consistent release profiles and high drug loading, thereby enhancing treatment efficacy and patient adherence.
Implementation Method 1
the stable nanoparticle compositions of buprenorphine utilize biodegradable polymers capable of degrading into non-toxic components in the body of an animal and may be excreted in the urine of the animal following their metabolism in the body
Implementation Method 2
the stable nanoparticle compositions are able to provide sustained or prolonged release of buprenorphine. In particular, the stable nanoparticle compositions are capable of releasing buprenorphine over several days, weeks, or months following administration
Data Source
AI summary
Stable nanoparticle compositions comprising buprenorphine and at least one biodegradable polymer. The disclosure also provides methods of controlling pain in an animal and methods of treating addiction in a human utilizing the stable nanoparticle compositions, as well as pharmaceutical formulations comprising the stable nanoparticle compositions. The stable nanoparticle compositions are capable of releasing buprenorphine over several days, weeks, or months following administration. The stable nanoparticle compositions of buprenorphine utilize biodegradable polymers capable of degrading into non-toxic components in the body of an animal and may be excreted in the urine of the animal following their metabolism in the body. The stable nanoparticle compositions can advantageously provide sustained release of buprenorphine in the body after a single administration without the need for surgical removal of implanted matrices subsequent to depletion of the drug.